Loss of FBXO11 establishes a stem cell program in acute myeloid leukemia by dysregulating LONP1 [RNA-seq]
RNA-seq (gene expression) · human · 23 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 23 samples: 8 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Loss of FBXO11 establishes a stem cell program in acute myeloid leukemia by dysregulating LONP1The Journal of clinical investigation · 2026
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE183843_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA762096 and SRA study SRP336419. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 23 samples.
How we read this: 8 replicated groups read from 23 sample titles; they account for 23 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM5572660 shCTR_1 shCT
- GSM5572661 shCTR_2 shCT
- GSM5572662 shCTR_3 shCT
- GSM5572663 shFBXO11_9_1 shFBXO11_9
- GSM5572664 shFBXO11_9_2 shFBXO11_9
- GSM5572665 shFBXO11_9_3 shFBXO11_9
- GSM5572666 shLONP1_1_1 shLONP1_1
- GSM5572667 shLONP1_1_2 shLONP1_1
- GSM5572668 shLONP1_1_3 shLONP1_1
- GSM5572669 Empty_1 Empty
- GSM5572670 Empty_2 Empty
- GSM5572671 Empty_3 Empty
- GSM5572672 FBXO11_1 FBXO11
- GSM5572673 FBXO11_2 FBXO11
- GSM5572674 FBXO11_3 FBXO11
- GSM5572675 LONP1_1 LONP1
- GSM5572676 LONP1_2 LONP1
- GSM5572677 LONP1_3 LONP1
- GSM5572678 shFBXO11_LONP1_1 shFBXO11_LONP1
- GSM5572679 shFBXO11_LONP1_2 shFBXO11_LONP1
- GSM5572680 shLONP1_FBXO11_1 shLONP1_FBXO11
- GSM5572681 shLONP1_FBXO11_2 shLONP1_FBXO11
- GSM5572682 shLONP1_FBXO11_3 shLONP1_FBXO11
- GSE183844 Loss of FBXO11 establishes a stem cell program in acute myeloid leukemia by dysregulating LONP1 32 samples shares fbxo11, lonp1, dysregulating, establishes, leukemia, program, myeloid
- GSE254991 Interleukin-16 Establishes a Th1-dominant Tumor Immune Microenvironment And Potentiates Immune Checkpoint Therapies [scRNA-Seq] 12 samples shares establishes, rna-seq
- GSE245461 CyCoNP lncRNA establishes cis and trans RNA-RNA interactions to supervise neuron physiology (RNA-seq). 6 samples shares establishes, rna-seq
- GSE287638 Proteasomal activation ameliorates neuronal phenotypes linked to FBXO11-deficiency [human] 6 samples shares fbxo11
- GSE291329 Omics of FBXO11-Mediated Proteolysis of BAHD1 Relieves PRC2-dependent Transcriptional Repression in Erythropoiesis 60 samples shares fbxo11
- GSE290717 FBXO11-Mediated Proteolysis of BAHD1 Relieves PRC2-dependent Transcriptional Repression in Erythropoiesis 10 samples shares fbxo11
- GSE331048 A Ligandable PNT-Domain Establishes ERG as a Directly Targetable Oncogenic Driver in Prostate Cancer 18 samples shares establishes
- GSE312326 DKC1 promotes colorectal cancer progression and therapy resistance by dysregulating sphingolipid biosynthesis 6 samples shares dysregulating
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.